159 related articles for article (PubMed ID: 23322750)
1. Identifying optimal postmarket surveillance strategies for medical and surgical devices: implications for policy, practice and research.
Gagliardi AR; Umoquit M; Lehoux P; Ross S; Ducey A; Urbach DR
BMJ Qual Saf; 2013 Mar; 22(3):210-8. PubMed ID: 23322750
[TBL] [Abstract][Full Text] [Related]
2. Implementing unique device identification in electronic health record systems: organizational, workflow, and technological challenges.
Campion TR; Johnson SB; Paxton EW; Mushlin AI; Sedrakyan A
Med Care; 2014 Jan; 52(1):26-31. PubMed ID: 24322986
[TBL] [Abstract][Full Text] [Related]
3. Oversight overhaul: eliminating the premarket review of medical devices and implementing a provider-centered postmarket surveillance strategy.
Scott B
Food Drug Law J; 2011; 66(3):377-404, ii. PubMed ID: 24505854
[TBL] [Abstract][Full Text] [Related]
4. Unique device identifiers for coronary stent postmarket surveillance and research: a report from the Food and Drug Administration Medical Device Epidemiology Network Unique Device Identifier demonstration.
Tcheng JE; Crowley J; Tomes M; Reed TL; Dudas JM; Thompson KP; Garratt KN; Drozda JP;
Am Heart J; 2014 Oct; 168(4):405-413.e2. PubMed ID: 25262248
[TBL] [Abstract][Full Text] [Related]
5. Factors influencing the reporting of adverse medical device events: qualitative interviews with physicians about higher risk implantable devices.
Gagliardi AR; Ducey A; Lehoux P; Turgeon T; Ross S; Trbovich P; Easty A; Bell C; Urbach D
BMJ Qual Saf; 2018 Mar; 27(3):190-198. PubMed ID: 28768712
[TBL] [Abstract][Full Text] [Related]
6. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
[TBL] [Abstract][Full Text] [Related]
7. Ethics, economics and the regulation and adoption of new medical devices: case studies in pelvic floor surgery.
Ross S; Weijer C; Gafni A; Ducey A; Thompson C; Lafreniere R
BMC Med Ethics; 2010 Aug; 11():14. PubMed ID: 20738887
[TBL] [Abstract][Full Text] [Related]
8. Postmarket surveillance for medical devices: America's new strategy.
Normand SL; Hatfield L; Drozda J; Resnic FS
BMJ; 2012 Oct; 345():e6848. PubMed ID: 23060660
[No Abstract] [Full Text] [Related]
9. US and European postmarket clinical data requirements.
Donawa M
Med Device Technol; 2005 Mar; 16(2):19-21. PubMed ID: 15828495
[TBL] [Abstract][Full Text] [Related]
10. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
11. Postmarket surveillance of natural health products in Canada: clinical and federal regulatory perspectives.
Murty M
Can J Physiol Pharmacol; 2007 Sep; 85(9):952-5. PubMed ID: 18066142
[TBL] [Abstract][Full Text] [Related]
12. Safe Medical Devices Act: management guidance for hospital compliance with the new FDA requirements.
Alder HC
Hosp Technol Ser; 1993 Oct; 12(11):1-27. PubMed ID: 10129209
[TBL] [Abstract][Full Text] [Related]
13. Risk management frameworks for human health and environmental risks.
Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
[TBL] [Abstract][Full Text] [Related]
14. Medical device accident reporting: does it improve patient safety?
Nobel JJ
Stud Health Technol Inform; 1996; 28():29-35. PubMed ID: 10172828
[TBL] [Abstract][Full Text] [Related]
15. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
Foy JM; Earls MF
Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
[TBL] [Abstract][Full Text] [Related]
16. Factors that influence the recognition, reporting and resolution of incidents related to medical devices and other healthcare technologies: a systematic review.
Polisena J; Gagliardi A; Urbach D; Clifford T; Fiander M
Syst Rev; 2015 Mar; 4():37. PubMed ID: 25875375
[TBL] [Abstract][Full Text] [Related]
17. Postmarketing surveillance of medical devices using Medicare claims.
Malenka DJ; Kaplan AV; Sharp SM; Wennberg JE
Health Aff (Millwood); 2005; 24(4):928-37. PubMed ID: 16012135
[TBL] [Abstract][Full Text] [Related]
18. Medical devices vigilance: the European approach.
Freeman MF
Stud Health Technol Inform; 1996; 28():13-6. PubMed ID: 10172826
[TBL] [Abstract][Full Text] [Related]
19. Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data.
Nelson JC; Cook AJ; Yu O; Dominguez C; Zhao S; Greene SK; Fireman BH; Jacobsen SJ; Weintraub ES; Jackson LA
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():62-71. PubMed ID: 22262594
[TBL] [Abstract][Full Text] [Related]
20. Postmarket surveillance. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2002 Jun; 67(109):38878-92. PubMed ID: 12053947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
